A fresh blow to the beta-amyloid hypothesis has not rattled Biogen's supporters, but Lilly shareholders were apparently hoping for more.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
The academic Dian-Tu study looks at anti-amyloid beta antibodies from Lilly and Roche; despite gantenerumab, hopes are being dialled back.
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
An upcoming study could show whether diabetes drugs like Novo’s Victoza might have an effect on slowing cognitive decline.
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.